Valuation : Addex Therapeutics Ltd

Market Cap 2.82M 3.45M 2.97M 2.55M 4.79M 330M 4.81M 33.44M 12.86M 168M 12.96M 12.68M 530M P/E 2024
0.8x
P/E 2025 -0.88x
Enterprise Value 1.21M 1.49M 1.28M 1.1M 2.06M 142M 2.07M 14.39M 5.54M 72.21M 5.58M 5.46M 228M EV / Sales 2024
5.67x
EV / Sales 2025 28.1x
Free-Float
43.94%
Yield 2024 *
-
Yield 2025 -
1 day-3.28%
1 week-15.11%
Current month-11.94%
1 month-41.58%
3 months-42.44%
6 months-47.56%
Current year-57.40%
1 week 0.02
Extreme 0.023
0.03
1 month 0.02
Extreme 0.023
0.07
Current year 0.02
Extreme 0.023
0.07
1 year 0.02
Extreme 0.023
0.07
3 years 0.02
Extreme 0.023
0.26
5 years 0.02
Extreme 0.023
1.54
10 years 0.02
Extreme 0.023
4
Manager TitleAgeSince
Chief Executive Officer 58 31/05/2013
Director of Finance/CFO 40 31/05/2017
Chief Tech/Sci/R&D Officer 69 27/11/2016
Director TitleAgeSince
Chairman 77 -
Director/Board Member 58 31/12/2014
Director/Board Member 81 11/05/2010
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/26 Issuer sale

Chief Technology Officer

-885,674 0.4051%
02/09/26 Issuer sale

Director

-539,122 0.2466%
02/09/26 Issuer sale

Chief Financial Officer

-1,205,816 0.5515%
Change 5-day change 1-year change 3-year change Capi.($)
-3.28%-15.11%-65.19%-68.45% 3.45M
-0.71%-6.35%-2.99%+9.37% 45.48B
+0.21%-2.98%+337.74%+520.30% 43.68B
+1.74%-2.24%+39.82%+20.85% 43.09B
+1.38%-3.28%+6.84%+73.19% 39.4B
-1.44%-5.26%+8.97%+39.76% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+19.75%+108.58% 16.4B
-0.31%-2.78%+10.78%+30.20% 14.24B
+1.93%-3.55%+82.00%+36.66% 13.28B
Average +0.11%-4.39%+48.63%+85.61% 26.48B
Weighted average by Cap. +0.41%-3.50%+74.56%+124.86%

Financials

2024 2025
Net sales 410K 503K 433K 372K 697K 48.02M 701K 4.87M 1.87M 24.43M 1.89M 1.85M 77.19M 173K 212K 183K 157K 294K 20.24M 295K 2.05M 789K 10.3M 796K 778K 32.54M
Net income 7.06M 8.65M 7.45M 6.4M 12M 826M 12.06M 83.8M 32.23M 420M 32.48M 31.77M 1.33B -6.73M -8.25M -7.11M -6.1M -11.44M -788M -11.5M -79.91M -30.73M -401M -30.97M -30.29M -1.27B
Net Debt -3.3M -4.04M -3.48M -2.99M -5.61M -386M -5.64M -39.19M -15.07M -197M -15.19M -14.86M -621M -1.6M -1.97M -1.69M -1.45M -2.73M -188M -2.74M -19.05M -7.33M -95.56M -7.38M -7.22M -302M
Logo Addex Therapeutics Ltd
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Employees
3
Date Price Change Volume
11/09/26 CHF 0.0236 -3.28% 883,456
10/09/26 CHF 0.0244 -2.40% 473,512
09/09/26 CHF 0.0250 -6.02% 1,078,504
08/09/26 CHF 0.0266 -1.48% 1,143,562
07/09/26 CHF 0.0270 -2.88% 538,082
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADXN Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!